Cullinan Therapeutics (NASDAQ:CGEM) Hits New 52-Week High – Here’s Why

Posted by Francis Steltz on Aug 17th, 2026

Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report)’s stock price reached a new 52-week high on Monday . The company traded as high as $21.22 and last traded at $20.9860, with a volume of 219959 shares traded. The stock had previously closed at $20.34.

Analysts Set New Price Targets

Several research analysts recently issued reports on CGEM shares. Wedbush increased their price target on shares of Cullinan Therapeutics from $39.00 to $42.00 and gave the stock an “outperform” rating in a research note on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Cullinan Therapeutics in a research note on Wednesday, July 8th. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Cullinan Therapeutics in a report on Monday. BTIG Research lifted their target price on shares of Cullinan Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Finally, Wall Street Zen lowered shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 1st. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Cullinan Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $32.86.

View Our Latest Report on CGEM

Cullinan Therapeutics Price Performance

The company has a market cap of $1.34 billion, a P/E ratio of -6.72 and a beta of 0.01. The company’s 50-day moving average is $17.05 and its two-hundred day moving average is $15.10.

Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.01). Equities research analysts anticipate that Cullinan Therapeutics, Inc. will post -3.04 EPS for the current year.

Insider Activity at Cullinan Therapeutics

In other news, insider Jennifer Michaelson sold 30,000 shares of the business’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $20.26, for a total value of $607,800.00. Following the completion of the transaction, the insider owned 162,844 shares in the company, valued at $3,299,219.44. The trade was a 15.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Cullinan Therapeutics

Institutional investors have recently modified their holdings of the business. Bank of America Corp DE bought a new stake in Cullinan Therapeutics in the 2nd quarter worth about $9,293,000. Boone Capital Management LLC purchased a new position in Cullinan Therapeutics in the 2nd quarter worth about $12,828,000. Jupiter Topco LLC bought a new position in Cullinan Therapeutics during the 2nd quarter valued at about $337,000. Elmind Capital LP bought a new position in Cullinan Therapeutics during the 2nd quarter valued at about $12,564,900,000. Finally, Legal & General Group Plc purchased a new stake in shares of Cullinan Therapeutics during the 2nd quarter valued at about $500,000. 86.31% of the stock is owned by hedge funds and other institutional investors.

About Cullinan Therapeutics

(Get Free Report)

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.